Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Cipher Pharmaceuticals ( (TSE:CPH) ) has shared an update.
Cipher Pharmaceuticals reported record 2025 results, with total revenue rising 51% to $50.5 million and net income up 137% to $27.3 million, driven primarily by the U.S. business where revenue surged 150% to $30.0 million. Adjusted EBITDA climbed 79% to $28.1 million and operating cash flow reached $29.7 million, underscoring strong profitability and cash generation.
The company strengthened its balance sheet by repaying $35.0 million of debt, ending 2025 with cash exceeding its remaining long-term debt and repurchasing $5.4 million of shares under its normal course issuer bid. Management highlighted the successful integration and outperformance of the acquired Natroba business, enhanced market positioning through preferred status on Illinois Medicaid, and a robust capital position, including access to $85 million in available debt financing, to pursue selective, accretive acquisitions for its next phase of growth.
The most recent analyst rating on (TSE:CPH) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on Cipher Pharmaceuticals stock, see the TSE:CPH Stock Forecast page.
Spark’s Take on TSE:CPH Stock
According to Spark, TipRanks’ AI Analyst, TSE:CPH is a Outperform.
The score is driven primarily by strong financial performance (notably cash flow quality, profitability, and reduced leverage). Earnings-call takeaways reinforce the strength via Natroba-led growth and debt repayment, while technical indicators are modestly positive. Valuation appears reasonable, but the lack of dividend yield data and headwinds in licensing/Absorica temper the overall rating.
To see Spark’s full report on TSE:CPH stock, click here.
More about Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company based in Mississauga, Ontario, focused on acquiring, developing, and commercializing branded dermatology and other specialty medicines in the U.S. and Canadian markets. Its portfolio includes Natroba, a U.S.-led product that has become a key growth driver, and Epuris, a Canadian dermatology product, reflecting a strategy centered on specialty therapeutics and targeted market niches.
Average Trading Volume: 26,652
Technical Sentiment Signal: Buy
Current Market Cap: C$366.3M
For a thorough assessment of CPH stock, go to TipRanks’ Stock Analysis page.